AI assistant
Innoviva, Inc. — Director's Dealing 2014
Jun 5, 2014
32090_dirs_2014-06-04_992e87a5-6995-449b-9863-9951b1e51891.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2014-06-02
Reporting Person: PEPE PAUL (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-06-02 | Common Stock | A | 6000 | — | Acquired | 6000 | Direct |
| 2014-06-02 | Common Stock | A | 6000 | — | Acquired | 12000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-06-02 | Stock Option (Right to Buy) | $23.0786 | A | 6000 | Acquired | 2024-06-01 | Common Stock (6000) | Direct |
| 2014-06-02 | Stock Option (Right to Buy) | $23.0786 | A | 6000 | Acquired | 2024-06-01 | Common Stock (6000) | Direct |
Footnotes
F1: The number of shares will be adjusted by a factor that is not determinable at the time of this filing to account for the effect of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc.
F2: This option may be exercised and shall be vested as to 1/24th of the shares subject to this option when optionee completes each continuous month of service following the grant date.
F3: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's stockholders provided the optionee remains in continuous service on such date.